Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Amygdala Neurosciences

Amygdala Neurosciences
2015 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
2 INVESTORS
Description

Developer of therapies designed to cure addiction. The company's therapies include a selective ALDH2 inhibitor that prevents surge in dopamine levels associated craving without changes to basal dopamine, enabling patients to quit and get rid of addiction to drugs, alcohol and smoking.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 509 Hale Street
  • Palo Alto, CA 94301
  • United States

+1 (650) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Amygdala Neurosciences’s full profile, request a free trial.

Amygdala Neurosciences Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 01-Apr-2019 00.000 Completed Startup
4. Grant 19-Sep-2018 000.00 00.000 Completed Startup
3. Seed Round 19-May-2017 00.000 00.000 000.00 Completed Startup
2. Seed Round 10-Feb-2017 $2M $3.45M 000.00 Completed Startup
1. Seed Round 10-Apr-2015 $1.45M $1.45M 000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Amygdala Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Seed-3 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 0.000
Seed-2 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed-1 5,307,464 $0.000100 $0.02 $0.27 $0.27 1x $0.27 25.3%
To view this company’s complete Cap Table, request access »

Amygdala Neurosciences Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0

Amygdala Neurosciences Executive Team (5)

Name Title Board
Seat
Contact
Info
Peter Strumph Co-Founder, President, Chief Executive Officer and Board Member
Adrienne MacMillan Co-Founder & Chief Financial Officer
Brent Blackburn Ph.D Co-Founder & Chief Development Officer
Ivan Diamond Ph.D Co-Founder, Board Member & Chief Scientific Officer
Louis Lange MD Co-Founder & Executive Chairman

Amygdala Neurosciences Board Members (6)

Name Representing Role Since Contact
Info
Howard Jaffe Amygdala Neurosciences Board Member 000 0000
Ivan Diamond Ph.D Amygdala Neurosciences Co-Founder, Board Member & Chief Scientific Officer 000 0000
Louis Lange MD Amygdala Neurosciences Co-Founder & Executive Chairman 000 0000
Mack Mitchell MD Self Board Member 000 0000
Peter Strumph Amygdala Neurosciences Co-Founder, President, Chief Executive Officer and Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »